IFG
ALNY icon

Independent Financial Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Independent Financial Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-630
Closed -$208K – 1553
2026
Q1 		$208K Sell
630
-68
-10% -$23.1K ﹤0.01% 1360
2025
Q4 		$278K Buy
698
+66
+10% +$29.2K 0.01% 1190
2025
Q3 		$288K Sell
632
-3
-0.5% -$1.22K 0.01% 1112
2025
Q2 		$207K Sell
635
-255
-29% -$70.6K 0.01% 1211
2025
Q1 		$240K Sell
890
-15
-2% -$3.85K 0.01% 1029
2024
Q4 		$213K Buy
+905
New +$238K 0.01% 1066

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Independent Financial Group's ALNY Position: Q2 2026 in Review

Independent Financial Group sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 630 shares — an estimated $208K sold.

Independent Financial Group first reported a position in ALNY in Q4 2024 and held it in 6 quarters. The position peaked at $288K in Q3 2025. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Independent Financial Group reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Independent Financial Group sold 630 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $208K.
  • Independent Financial Group first reported a position in Alnylam Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • Independent Financial Group's Alnylam Pharmaceuticals position peaked at $288K in Q3 2025.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Independent Financial Group's 13F filing for Q2 2026, filed 15 Jul 2026.